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94 Session: Disease & Treatmentmorphogenic proteins (BMPs) have also been tested as an adjunct therapy to
accelerate the healing of fractures. BMP is an expensive therapy and has not
been approved by the FDA for fracture treatment, only for spinal fusion.
Clearly, there is an unmet clinical need of a less expensive adjunct therapy
for better clinical management of fracture non-union. As a water-soluble mono-
mer isolated from Salviae miltiorrhizae, tanshinol has been proved to be an
effective bone anabolic agent with a high therapeutic index. However, its
high water solubility and lack of chemical stability, has impeded its clinical
application. To address this issue, we have developed a tanshinol-loaded
bone-targeting liposome formulation (Tan-BTL). The objective of this study
was to examine the potential therapeutic effects of Tan-BTL on fracture repair
in mice.
Methods: The bone-targeting liposome (BTL) was labelled by rhodamine B and was
used for a hydroxyapatite affinity test in vitro and a bone tissue targeting test in
vivo. The BTL was labelled by IRdye 800CW for the observation of its distribution
and retention time in the fracture site of mice. Tan-BTL (equivalent tanshinol dose
5 mg/kg, local administration once/week) was used for the treatment of a delayed
fracture healing mouse model (induced by daily administration of prednisone at
12 mg/kg for 64 days). Planar X ray image monitored the healing process of the
model for 64 days and the callus was analysed by micro-CT at the 18th day after
fracture.
Results: Tan-BTL demonstrated significant hydroxyapatite affinity in vitro. His-
tological analysis of the distal femur after local administration of the formula-
tion reveals robust targeting and retention at the growth plate, the trabecular
bone, the cortical bone, and bone lacuna. A near infrared imaging analysis
further confirmed BTL could concentrate on the fracture site of mice and be
retain there up to 20 days after local injection. When tested in a delayed frac-
ture healing mouse model (induced by daily administration of prednisone at
12 mg/kg for 64 days), micro-CT and planar X-ray imaging analysis of the callus
tissue suggests that Tan-BTL increased callus BV/TV by 54% in a femur fracture
of glucocorticoid-treated mice at the 18th day and shortened the fracture heal-
ing time from >64 days to 42 days when compared to glucocorticoid-treated
mice without treatment.
Conclusion: These results support BTL as a promising targeted drug delivery sys-
tem for local delivery of low molecular weight bone anabolic agents. Specifically,
the Tan-BTL formulation tested could be a simple, safe, and effective non-invasive
strategy for the treatment of bone fracture non-union.
http://dx.doi.org/10.1016/j.jot.2016.06.080231
ANGIOPOIETIN-LIKE PROTEIN 2 INDUCES INTERLEUKIN-6 EXPRESSION IN THE
MECHANISM UNDERLYING LIGAMENTUM FLAVUM HYPERTROPHY IN LUMBAR
SPINAL CANAL STENOSIS PATIENTS
Takayuki Nakamura, Kazuki Sugimoto, Hiroshi Mizuta
Kumamoto University, Japan
Introduction: Chronic inflammation is thought to cause ligamentum flavum (LF)
degeneration and hypertrophy in lumbar spinal canal stenosis (LSCS). Angiopoie-
tin-like protein 2 (Angptl2) is highly expressed in hypertrophied LF. Angptl2 regu-
lates interleukin-6 (IL-6) expression in various tissues, thus we investigated
whether IL-6 is expressed in hypertrophied LF and, if so, whether Angptl2 induces
IL-6 expression in LF fibroblasts.
Patients and Methods: LF tissue was obtained from LSCS patients and non-LSCS
patients. Polymerase chain reaction (PCR) for Angptl2 and IL-6 genes, and immu-
nohistochemistry for IL-6 protein were performed in LF tissue. Fibroblasts from
LF tissue were used for in vitro experiments. After Angptl2 recombinant protein
treatment, NF-kB activation and IL-6 expression in LF fibroblasts were
investigated by immunocytochemistry, PCR, and enzyme-linked immunosorbent
assay.
Results: IL-6 mRNA expression was increased in hypertrophied LF tissue from
LSCS patients and positively correlated with LF thickness and Angptl2 mRNA
expression. IL-6 protein was highly expressed in LF fibroblasts in hypertrophied
LF tissue. In vitro experiments demonstrated Angptl2 stimulation promoted
NF-kB nuclear translocation and induced IL-6 expression and secretion in LF
fibroblasts.
Discussion and Conclusion: This study provides evidence that Angptl2 could be a
key molecule causing and promoting inflammation in LF tissue by activating IL-6
expression. IL-6 mRNA expression and IL-6-expressed fibroblasts were increased
in hypertrophied LF compared with non-hypertrophied LF. Also, the expression
was positively correlated with LF thickness and Angptl2 expression. Our in vitro ex-
periments show that Angptl2 was able to elevate IL-6 expression via integrin a5b1/
NF-kB signalling in LF fibroblasts. Angptl2 could promote inflammation in LF tissue
by increasing IL-6 expression and secretion, resulting in LF degeneration and hy-
pertrophy in LSCS patients. Anti-Angptl2 treatment could serve as a target in novel
strategies for preventing LSCS and treating it.
http://dx.doi.org/10.1016/j.jot.2016.06.081246
MESENCHYMAL STEM CELLS PROMOTE VASCULOGENIC MIMICRY IN PROSTATE
CANCER THROUGH SDF-1/ CXCR4 AXIS AND PI3K/Akt PATHWAY
Liang Qin, An-min Chen, Feng-jing Guo, Qing Yang, Fei Xu, Ye Ren, Peng Cheng,
Hui Liao
Tongji Hospital, Tongji Medical College, Huazhong University of Science and
Technology, China
Background: Prostate cancer frequently metastasizes to the bone and the interac-
tion between cancer cells and the bone microenvironment has proven to be crucial
in the establishment of new metastases. Mesenchymal stromal cells (MSCs) in bone
marrow may enhance tumour metastasis through secreting various cytokines that
can regulate the behaviour of neighbouring cells. The term vasculogenic mimicry
(VM) refers to the unique capability of aggressive tumour cells to mimic the
pattern of embryonic vasculogenic networks. VM has been described in prostate
cancer and some other highly aggressive tumours and is associated with tumour
cell migration and invasion. However, the relationship between MSCs in their
native bone marrow microenvironment and VM formation is not clear. Here we
investigated the possible role of MSCs in VM by Prostate cancer cell lines, focusing
primarily on the SDF-1/CXCR4 Axes and PI3K/Akt pathway.
Subjects and Methods: We studied the underlying mechanisms of VM in prostate
cancer via the 3D culture system in vitro of PC-3 cells, expression of SDF-1,
CXCR4, Akt, p-Akt and VE-cadherin proteins/mRNAs determined by ELISA, immuno-
fluorescence, western blotting, and qRT-PCR, respectively.
Results: In this study, we show the effects of hMSCs on cancer cells are mediated
through a secreted factor(s). In addition to enhanced proliferation when in co-cul-
ture with hMSCs, PC-3 cells were found to have increased the VM formation and
CXCR4 expression in vitro. In addition, knocking down of CXCR4 using RNA interfer-
ence or inhibition of CXCR4 function by an antagonist AMD3100 blocked hMSC-
induced VM formations of PC-3 cells. Furthermore, hMSCs increased phosphoryla-
tion of Akt. Additionally, blocking PI3K/Akt Pathway using a PI3K inhibitor
LY294002 decreased hMSCs induced VM formations of PC-3 cells. Under in vivo con-
ditions, tumour growth and VM formation was promoted by MSCs in nude mice.
Discussion and Conclusion: To our knowledge, this is the first report discussing the
relationship between MSCs and VM of cancer cells. This study establishes that MSCs
in the bone microenvironment might promote the VM formations of Prostate can-
cer and points to SDF-1/CXCR4 axis and PI3K/Akt pathway as a potential target for
therapeutic intervention. Better understanding of the mechanisms involved in this
tumour stoma cell interaction may provide novel targets for the development of
treatment strategies for prostate to bone metastasis.
http://dx.doi.org/10.1016/j.jot.2016.06.082248
ASSOCIATION OF 3q13.32 VARIANTS WITH HIP TROCHANTER AND
INTERTROCHANTER BONE MINERAL DENSITY IDENTIFIED BY A GENOME-WIDE
ASSOCIATION STUDY
Lei Zhang a,b, Zong-Gang Xie c, Wen-Zhu Hu a,b, Shu Ran e, Yong Lin e, Rong Hai f,
Hui Shen g, Qing Tian g, Yong-Hong Zhang b,d, Shu-Feng Lei a,b, Christopher
J. Papasian h, Hong-Wen Deng g, Yu-Fang Pei b,d
aCenter for Genetic Epidemiology and Genomics, School of Public Health, Medical
College of Soochow University, Jiangsu, PR China
bJiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric
Diseases, China
cThe Second Affiliated Hospital of Soochow University, China
dDepartment of Epidemiology and Health Statistics, China
eCenter of System Biomedical Sciences, University of Shanghai for Science and
Technology, Shanghai, PR China
fInner Mongolia Autonomous Region People’s Hospital, Hohhot, Inner Mongolia, PR
China
gDepartment of Biostatistics and Bioinformatics, Tulane University School of
Public Health and Tropical Medicine, New Orleans, Louisiana, USA
hDepartment of Basic Medical Science, University of Missouri-Kansas City, Kansas
City, MO, USA
Object: Hip trochanter (TRO) and intertrochanter (INT) sub-regions have impor-
tant clinical relevance to subtrochanteric and intertrochanteric fractures, but
have rarely been studied by genome-wide association studies (GWASs).
Subjects and Methods: Aiming to identify genomic loci associated with BMD vari-
ation at TRO and INT regions, we performed a GWAS utilising the Framingham heart
study (FHS, NZ6,912) as a discovery sample, and utilised the Women’s health
initiative (WHI) African-American sub-sample (NZ845), WHI Hispanic sub-sample
(NZ446), and Omaha osteoporosis study (NZ963), for replication.
Results: Combining the evidence from both discovery and replication samples, we
identified one novel locus, 3q13.32 (rs1949542, discovery pZ6.16x10-8, replica-
tion pZ2.86x10-4 for INT-BMD; discovery pZ1.35x10-7, replication pZ4.16x10-4
Session: Disease & Treatment 95for TRO-BMD, IGSF11). We also replicated two loci 3p21 (rs148725943, discovery
pZ6.61x10-7, replication pZ5.22x10-4 for TRO-BMD, CTNNB1) and 8q24
(rs7839059, discovery pZ2.28x10-7, replication pZ1.55x10-3 for TRO-BMD,
TNFRSF11B) that were reported previously.
Conclusion: Our findings provide useful insights that enhance our understanding of
bone development, osteoporosis, and fracture pathogenesis.
http://dx.doi.org/10.1016/j.jot.2016.06.083253
PHOTODYNAMIC THERAPY (PDT) TO ENHANCE HEALING OF FEMUR FRACTURES
WITH A CRITICALLY SIZED DEFECT
Margarete Akens a,c, Michael Hardisty b, Diane Nam b,c, Albert Yee b,c,
Brian Wilson a,c, Cari Whyne b,c
aUniversity Health Network, Canada
bSunnybrook Research Institute, Canada
cUniversity of Toronto, Canada
Introduction: Themajority of long bone fractures heal successfully without compli-
cations; however fractures resulting from high impact trauma can result in delayed
healing or non-union. Early intervention could decrease patient morbidity and
reducehealth care systemcosts. Photodynamic therapy (PDT) is aminimally invasive
local treatment involving administration of a photosensitizer, which is activated by
laser light leading to the production of singlet oxygen, which can induce apoptosis
and/or necrosis of targeted cells and tissue and also influence immune responses.
PDT treatment of metastatically involved vertebrae resulted in improved vertebral
bone strength, stiffness and architecture,motivating studying PDTas an approach to
augment bone healing. The aim of this studywas to evaluate the ability of PDT treat-
ment to enhance healing in fractures exhibiting critically size defects.
Materials and Methods: Femoral fractures with critically sized defects (6 mm)
were generated in 30 adult female Sprague-Dawley rats (7 or 15 week survival).
Under general anaesthesia an 8-hole PEEK plate was attached laterally to the fe-
mur. Using a Gigly saw, a bone piece was removed followed by closure of muscu-
lature and skin. Rats were randomly allocated to three groups: control, PDT
applied either 1 day, or 7 days post fracture. A photosensitizer (Visudyne, Novartis,
Canada) was injected (1mg/kg) followed 15 minutes later by light delivery (75J;
690 nm) using a 1 cm diffuser fibre placed parallel to the fracture. The rats
were euthanized 7 or 15 weeks after induction of the fracture. mCT images of
the femur at an isotropic 13.3 mm/voxel resolution (Inveon MicroCT, Siemens, Ger-
many) were acquired and analysed (AmiraDev 5.2, FEI Visualization Science Group,
USA). Thereafter, the bone was decalcified and processed for histology. Statistical
analysis was performed using a 1-way ANOVA.
Results: All rats recovered well; however five animals were euthanized early due
to plate displacement. The total bone volume (TV) evaluated from mCT images
within the fracture gap did not show significant differences. In contrast, BMD
(gHA/cm2) trended toward higher values in the PDT treated groups compared to
controls. The fracture gap measured on mCT images of the 7 week group demon-
strated a trend toward smaller gaps in the PDT treated groups (pZ 0.0535). A sta-
tistically significant (pZ 0.0085) smaller gap is present in the PDT treated groups
after 15 weeks. Histology of the control group showed more cartilage and woven
bone formation in contrast to the PDT treated groups which exhibited more struc-
tured and mature bone.
Discussion: PDT treatment of rat femur fractures led to lower overall formation of
bone, but the bone had higher density with a decrease in the size of the fracture
gap. The increase in bone density in the PDT treated groups may suggest formation
of better quality bone (vs. quantity of bone). Histologically, with more cartilage
and woven bone present in the control group in contrast to more mature bone
and in the PDT group, the fracture healing seems to follow a different pattern,
which requires further investigation.
Funding/support: Congressionally directed Medical Research programs (CDMRP),
grant # OR090260.
http://dx.doi.org/10.1016/j.jot.2016.06.084258
PATHOPHYSIOLOGY OF CHEMOTHERAPY-INDUCED DAMAGE OF BONE MARROW
MICRO-VASCULATURE AND POTENTIAL PROTECTIVE EFFECTS OF FLAVONOIDS
IN RATS
Mohammadhossein Hassanshahi
University of South Australia, Australia
Introduction: It has been widely shown that bone formation and remodelling
would not occur unless there is already a properly established micro-vasculature.
However, blood vessels can be damaged by extrinsic causes such as chemothera-
peutic agents. Methotrexate (MTX) is an anti-metabolite chemo-agent widely
used in treatment of many diseases including childhood leukaemia and inflamma-
tory disorders. While previous studies showed that MTX can cause long-term skel-
etal side effects, whether and how it damages bone marrow micro-vasculatureremains unclear. Using a rat model and endothelial cell-culture models, we
addressed these questions. In addition, since we recently showed that the osteo-
genic, anti-oxidant, and anti-inflammatory flavonoid genistein can protect bone in
MTX-treated rats, here we also investigated effects of genistein in the recovery of
damaged blood vessels in rats treated with MTX. Furthermore, we also examined
potential treatment effects of genistein and a related flavonoid, icariin, on
viability and tube-formation ability of endothelial cells treated with MTX in vitro.
Methods: Animal studies: To study the effect of MTX on blood vessels, groups of
male (6-week-old) SpragueeDawley rats were subcutaneously injected with MTX
(0.75mg/kg) once daily for 5 days and were sacrificed on day 1, 3, 6, 9, 11, and
14. To study the protective effects of genistein, in some MTX-treated rats, genis-
tein was administrated by oral gavage (2 mg/100 g BW) for the whole period start-
ing from day 0 until one day before kill (day 9). Treatment effects on number and
sizes of bone marrow micro blood vessels were examined histologically in tibiae.
MTT viability assay: Concentration-/time- dependent treatment effects of MTX
(10nM-10mM) were examined on viability of cultured rat sinusoid endothelial cells
(SECs) and effects of 24 hour treatment with MTX plus icariin/genistein (10nM-
10mM) were also studied. Apoptosis detection by flow cytometry: SECs were
treated with MTX (1mM/mL) for 24 and 48 hours and apoptosis was detected based
on their cell surface Annexin-V expression. Tube formation assay: SECs were
treated with/without MTX (1mM), icariin or genistein (100nM-10mM) and effects
on angiogenesis were examined based on formation of tubes by SECs on Matrigel.
Results: Histological image analyses of H&E-stained tibial sections showed significant
blood vessel damage in the bone marrow of rats on days 6 and 9 and significant but
partial recovery ondays 11 and 14 following the first MTX dose.Histologyanalyses sug-
gested that genistein potentially attenuates MTX-induced blood vessel damage in the
bone marrow. Examining any cytotoxic effect of MTX on endothelial cells, MTTassays
showed that the viability of SECs was not affected after 24 hours of treatment with
MTX (10nM-10mM). However, following 48 hour treatment, viability of SECs was
reduced in a concentration-dependant manner. Flow cytometry analysis revealed
that SECs underwent apoptosis following 48 hours (but not 24 hours) treatment with
MTX (1mM). MTT assays also showed that neither genistein nor icariin treatment
affected viability of SECs viability. Tube formation assays showed a reduced tube for-
mation potential of SECs treated with MTX (1mM). Interestingly, icariin or genistein
(10mM)-treated SECs showed enhanced tube formation and icariin or genistein treat-
ment can prevent MTX-induced decrease in tube formation.
Discussion and Conclusion: Our in vivo and in vitro studies suggest that MTX
causes blood vessel damage in the bone marrow, potentially by inducing apoptosis
in endothelial cells and also interfering in the process of angiogenesis. Our in vitro
tube formation assays showed that icariin and genistein might not only promote
angiogenesis but possess some protective effect against MTX damage. Consis-
tently, our in vivo studies also showed some positive effects of genistein treatment
in reducing MTX-induced blood vessel damage in the bone marrow of rats.
http://dx.doi.org/10.1016/j.jot.2016.06.085259
INCREASED EZH2 COMBINED WITH DECREASED OSTEOBLASTOGENESIS IN
LOCAL IRRADIATION INDUCED RAT BONE LOSS
Changjun Guo, Changwei Li, Lianfu Deng
Shanghai Institute of Traumatology and Orthopaedics, China
Radiation therapy is a common treatment for cancer patients. The adverseeffects are
the insufficiency fractures and bone loss. Epigenetic regulation plays an important
role in the BMSCs differentiation. We reported here, the changes of local bone after a
single-dose 137CS irradiation exposure in rats. The bone mineral density (BMD) of the
femur and the trabecular bone volume in the tibia were significantly decreased at 12
weeks after irradiation. The micro-CT results showed that the tBMD, Tb.h, and Tb.N
were also significantly reduced after 12 weeks of irradiation exposure. The ALP-pos-
itive OB.S/BS was decreased by 42.3% after 2 weeks irradiation, and decreased by
50.8% at the 12 weeks. In contrast to the decreased expression of Runx2 and BMP2,
we found EZH2 expression was significantly increased after 2 weeks of single-dose
137CS irradiation in BMSCs. In conclusion, our results demonstrated that the single-
dose 137CS irradiation induces the loss of BMD and bone micro-architecture deteriora-
tion in rat skeleton,aswell as the increasedexpression of EZH2anddecrease of osteo-
blastogenesis after irradiation. The underlying mechanisms may be required to
further investigate the relationship.
http://dx.doi.org/10.1016/j.jot.2016.06.086261
MYRICITRIN INHIBITS OSTEOCLASTOGENESIS
Weiguang Lu, Liu Yang, Zhuojing Luo
The Fourth Military Medical University, Xijing Hospital, China
Myricitrin is a botanical flavonol glycoside, extracted from leaves of Myrica ceri-
fera and other plants. Abundant evidence supports myricitrin has anti-oxidative,
anti-inflammatory, and neuroprotective effects. Osteoclastic bone resorption is
